

# Arthur M Feldman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1605826/publications.pdf>

Version: 2024-02-01

80  
papers

4,044  
citations

147801

31  
h-index

118850

62  
g-index

81  
all docs

81  
docs citations

81  
times ranked

4809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. <i>Nature Communications</i> , 2021, 12, 2942.	12.8	62
2	The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy. <i>JACC: Heart Failure</i> , 2021, 9, 439-449.	4.1	10
3	Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	34
4	Novel BAG3 Variants in African American Patients With Cardiomyopathy: Reduced $\beta$ -Adrenergic Responsiveness in Excitation-Contraction. <i>Journal of Cardiac Failure</i> , 2020, 26, 1075-1085.	1.7	5
5	To Breastfeed or Not to Breastfeed With Peripartum Cardiomyopathy. <i>JACC Basic To Translational Science</i> , 2019, 4, 301-303.	4.1	7
6	Letter by Feldman et al Regarding Article, "Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery". <i>Circulation</i> , 2019, 140, e5-e6.	1.6	0
7	Role of Bcl2-associated Athanogene 3 in Turnover of Gap Junction Protein, Connexin 43, in Neonatal Cardiomyocytes. <i>Scientific Reports</i> , 2019, 9, 7658.	3.3	13
8	Current Landscape of Heart Failure Gene Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e012239.	3.7	45
9	Precision Medicine for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1185-1188.	2.8	1
10	Mitochondrial dysfunction in human immunodeficiency virus-1 transgenic mouse cardiac myocytes. <i>Journal of Cellular Physiology</i> , 2019, 234, 4432-4444.	4.1	14
11	Lamin B is a target for selective nuclear PQC by BAG3: implication for nuclear envelopathies. <i>Cell Death and Disease</i> , 2019, 10, 23.	6.3	8
12	Trpm2 enhances physiological bioenergetics and protects against pathological oxidative cardiac injury: Role of Pyk2 phosphorylation. <i>Journal of Cellular Physiology</i> , 2019, 234, 15048-15060.	4.1	10
13	Restoring public trust in scientific research by reducing conflicts of interest. <i>Journal of Clinical Investigation</i> , 2019, 129, 3971-3973.	8.2	4
14	Genetic Testing for Inherited Cardiac Diseases in Underserved Populations of Non-European Ancestry. <i>JAMA Cardiology</i> , 2018, 3, 273.	6.1	14
15	The Multifunctional Protein BAG3. <i>JACC Basic To Translational Science</i> , 2018, 3, 122-131.	4.1	40
16	Haploinsufficiency of Bcl2-associated athanogene 3 in mice results in progressive left ventricular dysfunction, $\beta$ -adrenergic insensitivity, and increased apoptosis. <i>Journal of Cellular Physiology</i> , 2018, 233, 6319-6326.	4.1	32
17	The Heart-Brain Continuum: A New Way of Looking at Heart Failure Therapy. <i>Journal of Cardiac Failure</i> , 2018, 24, 537-539.	1.7	0
18	Association of Variants in <i>BAG3</i> With Cardiomyopathy Outcomes in African American Individuals. <i>JAMA Cardiology</i> , 2018, 3, 929.	6.1	57

#	ARTICLE	IF	CITATIONS
19	A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality. <i>Journal of Clinical Investigation</i> , 2018, 128, 1154-1163.	8.2	34
20	Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting. <i>Circulation</i> , 2017, 135, 1136-1144.	1.6	21
21	Precision Medicine for Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	9
22	An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin Inhibition. <i>JACC: Heart Failure</i> , 2017, 5, 851-852.	4.1	0
23	Evidence for the Role of BAG3 in Mitochondrial Quality Control in Cardiomyocytes. <i>Journal of Cellular Physiology</i> , 2017, 232, 797-805.	4.1	60
24	Adeno-Associated Virus Serotype 9-Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts With Left Ventricular Dysfunction Secondary to a Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2016, 1, 647-656.	4.1	32
25	Neprilysin Inhibition in the Time of Precision Medicine —. <i>JACC: Heart Failure</i> , 2016, 4, 409-414.	4.1	9
26	Vasopressin type 1A receptor deletion enhances cardiac contractility, $\beta^2$ -adrenergic receptor sensitivity and acute cardiac injury-induced dysfunction. <i>Clinical Science</i> , 2016, 130, 2017-2027.	4.3	6
27	GRP78 Interacting Partner Bag5 Responds to ER Stress and Protects Cardiomyocytes From ER Stress-Induced Apoptosis. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1813-1821.	2.6	48
28	BAG3 regulates contractility and Ca <sup>2+</sup> homeostasis in adult mouse ventricular myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2016, 92, 10-20.	1.9	56
29	Valsartan/Sacubitril for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 25.	7.4	38
30	Arginine vasopressin receptor signaling and functional outcomes in heart failure. <i>Cellular Signalling</i> , 2016, 28, 224-233.	3.6	37
31	Bcl-2-associated athanogene 3 protects the heart from ischemia/reperfusion injury. <i>JCI Insight</i> , 2016, 1, e90931.	5.0	40
32	A Metric-Based System for Evaluating the Productivity of Preclinical Faculty at an Academic Medical Center in the Era of Clinical and Translational Science. <i>Clinical and Translational Science</i> , 2015, 8, 357-361.	3.1	9
33	Bench-to-Bedside; Clinical and Translational Research; Personalized Medicine; Precision Medicine — What's in a Name?. <i>Clinical and Translational Science</i> , 2015, 8, 171-173.	3.1	20
34	Incorporating Clinical and Translational Science into the Undergraduate Medical Education Curriculum. <i>Clinical and Translational Science</i> , 2015, 8, 267-267.	3.1	5
35	Clinical and Translational Science (CTS): 2005–2015. <i>Clinical and Translational Science</i> , 2015, 8, 621-622.	3.1	1
36	An observational pre-post study of re-structuring Medicine inpatient teaching service: Improved continuity of care within constraint of 2011 duty hours. <i>Healthcare</i> , 2015, 3, 129-134.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Undergraduate medical education in the U.S. and Israel: contrasts and common challenges. <i>Israel Journal of Health Policy Research</i> , 2015, 4, 56.	2.6	1
38	Ivabradine in Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 65, 549-551.	1.9	1
39	Cardiac Dysfunction in HIV-1 Transgenic Mouse: Role of Stress and BAG3. <i>Clinical and Translational Science</i> , 2015, 8, 305-310.	3.1	20
40	American medical education at a crossroads. <i>Science Translational Medicine</i> , 2015, 7, 285fs17.	12.4	8
41	Ca <sup>2+</sup> entry via Trpm2 is essential for cardiac myocyte bioenergetics maintenance. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 308, H637-H650.	3.2	57
42	miR-146a targets c-Fos expression in human cardiac cells. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1081-91.	2.4	35
43	Regulation of L-type calcium channel by phospholemman in cardiac myocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 84, 104-111.	1.9	18
44	Whole transcriptome microarrays identify long non-coding RNAs associated with cardiac hypertrophy. <i>Genomics Data</i> , 2015, 5, 68-71.	1.3	6
45	Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials. <i>Cardiology</i> , 2015, 130, 69-81.	1.4	4
46	Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. <i>Science Translational Medicine</i> , 2015, 7, 277ra31.	12.4	126
47	BAG3: a new player in the heart failure paradigm. <i>Heart Failure Reviews</i> , 2015, 20, 423-434.	3.9	79
48	The Bayh-Dole Act, A Lion without Claws. <i>Clinical and Translational Science</i> , 2015, 8, 3-4.	3.1	2
49	Decreased Levels of BAG3 in a Family With a Rare Variant and in Idiopathic Dilated Cardiomyopathy. <i>Journal of Cellular Physiology</i> , 2014, 229, 1697-1702.	4.1	68
50	The National Institutes of Health Physician-Scientist Workforce Working Group Report: A Roadmap for Preserving the Physician-Scientist. <i>Clinical and Translational Science</i> , 2014, 7, 289-290.	3.1	60
51	Mixing Politics and Medicine: A Case Study. <i>Clinical and Translational Science</i> , 2014, 7, 351-353.	3.1	0
52	Increased Vasopressin 1A Receptor Expression in Failing Human Hearts. <i>Journal of the American College of Cardiology</i> , 2014, 63, 375-376.	2.8	21
53	TRPM2 Channels Protect against Cardiac Ischemia-Reperfusion Injury. <i>Journal of Biological Chemistry</i> , 2014, 289, 7615-7629.	3.4	78
54	Response to "Clarification of Enrolled Subjects in Tolvaptan HF Trials". <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 661-661.	4.7	0

#	ARTICLE	IF	CITATIONS
55	$\beta^2$ -Adrenergic Receptor-Mediated Cardiac Contractility Is Inhibited via Vasopressin Type 1A-Receptor-Dependent Signaling. <i>Circulation</i> , 2014, 130, 1800-1811.	1.6	34
56	G-Protein Beta-3 Subunit Genotype Predicts Enhanced Benefit of Fixed-Dose Isosorbide Dinitrate and Hydralazine. <i>JACC: Heart Failure</i> , 2014, 2, 551-557.	4.1	40
57	Vasopressin Antagonists for Patients With Acute Heart Failure: Interpreting New Clinical and Translational Data. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 373-375.	4.7	7
58	Induced Overexpression of Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger Does Not Aggravate Myocardial Dysfunction Induced by Transverse Aortic Constriction. <i>Journal of Cardiac Failure</i> , 2013, 19, 60-70.	1.7	16
59	Coordinated Regulation of Cardiac Na <sup>+</sup> /Ca <sup>2+</sup> Exchanger and Na <sup>+</sup> -K <sup>+</sup> -ATPase by Phospholemman (FXD1). <i>Advances in Experimental Medicine and Biology</i> , 2013, 961, 175-190.	1.6	20
60	The second member of transient receptor potential-melastatin channel family protects hearts from ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H1010-H1022.	3.2	62
61	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. <i>Circulation: Heart Failure</i> , 2013, 6, 461-472.	3.9	28
62	Academic Medical Centers: Too Big to Fail. <i>Clinical and Translational Science</i> , 2013, 6, 419-420.	3.1	1
63	Publishing "Invisible" and "Abandoned" Clinical Trials: A Commitment for CTS. <i>Clinical and Translational Science</i> , 2013, 6, 251-253.	3.1	3
64	Constitutive overexpression of phosphomimetic phospholemman S68E mutant results in arrhythmias, early mortality, and heart failure: potential involvement of Na <sup>+</sup> /Ca <sup>2+</sup> exchanger. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012, 302, H770-H781.	3.2	26
65	On Being a Chair of Medicine in 2012. <i>American Journal of Medicine</i> , 2012, 125, 315-319.	1.5	2
66	Publishing Genomic Studies: Walking the Fine Line. <i>Clinical and Translational Science</i> , 2012, 5, 1-2.	3.1	2
67	Federal Politics and the Clinical and Translational Sciences. <i>Clinical and Translational Science</i> , 2011, 4, 395-396.	3.1	0
68	The Development of $\beta^2$ -Adrenergic Receptor Antagonists for the Treatment of Heart Failure: A Paradigm for Translational Science. <i>Circulation Research</i> , 2011, 109, 1173-1175.	4.5	2
69	Controlled and Cardiac-Restricted Overexpression of the Arginine Vasopressin V1A Receptor Causes Reversible Left Ventricular Dysfunction Through G <sub>i</sub> -Mediated Cell Signaling. <i>Circulation</i> , 2011, 124, 572-581.	1.6	44
70	Regulation of in vivo cardiac contractility by phospholemman: role of Na <sup>+</sup> /Ca <sup>2+</sup> exchange. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H859-H868.	3.2	33
71	Phospholemman and $\beta^2$ -adrenergic stimulation in the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H807-H815.	3.2	31
72	Induced overexpression of Na <sup>+</sup> /Ca <sup>2+</sup> exchanger transgene: altered myocyte contractility, [Ca <sup>2+</sup> ] <sub>i</sub> transients, SR Ca <sup>2+</sup> contents, and action potential duration. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H590-H601.	3.2	44

#	ARTICLE	IF	CITATIONS
73	Endothelial Nitric Oxide Synthase (NOS3) Polymorphisms in African Americans With Heart Failure: Results From the A-HeFT Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, 191-198.	1.7	69
74	Regulation of cardiac myocyte contractility by phospholemman: Na <sup>+</sup> /Ca <sup>2+</sup> exchange versus Na <sup>+</sup> -K <sup>+</sup> -ATPase. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H1615-H1625.	3.2	44
75	Aldosterone Synthase Promoter Polymorphism Predicts Outcome in African Americans With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1277-1282.	2.8	89
76	Rationale and Design of the Enoximone Clinical Trials Program. <i>Journal of Cardiac Failure</i> , 2005, 11, 659-669.	1.7	26
77	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. <i>Circulation</i> , 2004, 109, 1594-1602.	1.6	1,062
78	Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2019-2026.	2.8	149
79	Results of Targeted Anti-Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 1044-1047.	1.6	358
80	Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 1993, 329, 149-155.	27.0	484